Skip to main content

Hims & Hers Health Inc. (HIMS)

Computer Software and Services Information Technology
Stock AI

Financial Metrics

Price to Earnings-524.12x
Revenue Growth (1Y)32.81%
Debt to Equity2.2x

Strengths

Stock Chart

Valuation

Hims & Hers Health Inc. is overvalued

News

All
Press Releases
News
Filings
HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.
August 10, 2026Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.
Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.
August 10, 2026Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.
Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
August 10, 2026Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
HIMS & HERS HEALTH, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Hims & Hers Health, Inc.’s Directors and Officers for Breach of Fiduciary Duties – HIMS
August 10, 2026HIMS & HERS HEALTH, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Hims & Hers Health, Inc.’s Directors and Officers for Breach of Fiduciary Duties – HIMS
Hims & Hers Introduces New Hers App with First-of-Its-Kind, Doctor-Led, AI-Native Care Experience
August 06, 2026Hims & Hers Introduces New Hers App with First-of-Its-Kind, Doctor-Led, AI-Native Care Experience
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
August 03, 2026NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law
July 30, 2026HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
July 30, 2026Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
July 30, 2026Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Hims & Hers Stock Plunges After FTC Sues Over Alleged Privacy Violations
July 29, 2026Hims & Hers Stock Plunges After FTC Sues Over Alleged Privacy Violations
Hims and Hers shares fall 10% as FTC sues company over data, billing practices
July 29, 2026Hims and Hers shares fall 10% as FTC sues company over data, billing practices
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
July 29, 2026Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Hims & Hers Responds to FTC Lawsuit
July 29, 2026Hims & Hers Responds to FTC Lawsuit
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
July 17, 2026Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
July 13, 2026Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know
June 16, 2026Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know
Hims & Hers Stock Is Surging Monday: What's Driving The Move?
June 15, 2026Hims & Hers Stock Is Surging Monday: What's Driving The Move?
Hims & Hers Health Stock Slides Friday: What's Going On?
June 12, 2026Hims & Hers Health Stock Slides Friday: What's Going On?
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
June 04, 2026Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
June 02, 2026Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
June 02, 2026Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
June 02, 2026Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
June 02, 2026Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
May 29, 2026Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
May 28, 2026Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
May 27, 2026Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
Hims & Hers Shares Rally On Million-Dollar Insider Purchase
May 27, 2026Hims & Hers Shares Rally On Million-Dollar Insider Purchase
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
May 21, 2026Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
May 21, 2026Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
Why Is Hims & Hers Stock Sinking Monday?
May 18, 2026Why Is Hims & Hers Stock Sinking Monday?
$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today
May 15, 2026$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today
Nasdaq 100 Dips On Hot CPI, Sandisk And Micron Tumble 9%: Stock Market Today
May 12, 2026Nasdaq 100 Dips On Hot CPI, Sandisk And Micron Tumble 9%: Stock Market Today
Why Is Hims & Hers Stock Sinking Tuesday?
May 12, 2026Why Is Hims & Hers Stock Sinking Tuesday?
Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance
May 12, 2026Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance
Why Hims & Hers Health Are Falling Monday
May 11, 2026Why Hims & Hers Health Are Falling Monday
Stock Market Today: S&P 500, Dow Futures Fall As Trump Rejects 'Totally Unacceptable' Iran Peace Proposal—Micron Technologies, Moderna In Focus
May 11, 2026Stock Market Today: S&P 500, Dow Futures Fall As Trump Rejects 'Totally Unacceptable' Iran Peace Proposal—Micron Technologies, Moderna In Focus
Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
May 11, 2026Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
10-Q Quarterly Report for 2026 Q1
May 11, 202610-Q Quarterly Report for 2026 Q1
EXCLUSIVE: Enhanced CEO Says Its Performance Medicine Platform Is The Real Prize Beyond The Games
April 29, 2026EXCLUSIVE: Enhanced CEO Says Its Performance Medicine Platform Is The Real Prize Beyond The Games
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
April 28, 2026Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
April 27, 2026This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.
April 23, 2026Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
April 23, 2026Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
April 16, 2026RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
How RFK Jr. Is Sending Hims & Hers Stock Higher
April 16, 2026How RFK Jr. Is Sending Hims & Hers Stock Higher
FDA To Review Easing Grip On Several Peptide Therapies Popular Among Influencers And Fitness Gurus In Potential Win For RFK Jr.
April 16, 2026FDA To Review Easing Grip On Several Peptide Therapies Popular Among Influencers And Fitness Gurus In Potential Win For RFK Jr.
Why Is Hims & Hers Stock Soaring After FDA's Announcment?
April 16, 2026Why Is Hims & Hers Stock Soaring After FDA's Announcment?
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
April 13, 2026Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
April 03, 2026Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
March 31, 2026Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
March 26, 2026Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
March 23, 2026India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
March 19, 2026Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
Hims & Hers Health Stock Slips After Surging 50% In A Month
March 16, 2026Hims & Hers Health Stock Slips After Surging 50% In A Month
OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
March 14, 2026OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week

A. Company Overview

Hims & Hers Health, Inc. is a health and wellness company established in 2017, designed to provide consumers with modern, personalized healthcare solutions through a digital-first platform. The organization operates with a consumer-first approach, seeking to transform how individuals access and fulfill their health and wellness needs. Hims & Hers combines technology with a vast network of licensed healthcare providers to facilitate telehealth consultations that address a range of conditions—from sexual health and hair loss to dermatology, mental health, and weight loss.

The Hims & Hers platform is built on a robust technological infrastructure that includes a clinically-focused electronic medical record system, digital prescriptions, and cloud-based pharmacy fulfillment services. This system allows users to engage with licensed healthcare professionals, who may prescribe medications when deemed appropriate, thus streamlining the processes of consultation and delivery. This digital accessibility supports the company’s mission to help consumers achieve better health, aiming to normalize the act of seeking medical treatment and providing personalized care in an omnichannel way.

Since its inception, Hims & Hers has conducted nearly twenty million telehealth consultations, making healthcare more accessible, convenient, and cost-effective for consumers across all 50 states and the United Kingdom. In addition to digital offerings, its products are made available in tens of thousands of retail locations nationwide.

B. Business Strategy

Hims & Hers focuses on a subscription-based model, offering health and wellness products and services directly to consumers via its website and mobile applications. Its offerings primarily address conditions that require ongoing management through prescription medications and healthcare provider relationships. The company sells over-the-counter products, including skincare, sexual health products, and supplements, both online and through partnerships with retail outlets.

The company's business strategy relies on a unique blend of technology, brand trust, and clinical excellence. The platform utilizes proprietary algorithms to pair customer needs with healthcare solutions, enhancing the customer experience by making it seamless to follow up on treatment plans.

Most products are offered on a subscription basis, enabling customers to select delivery cadences from 30 days to as long as 360 days. Customers are billed automatically, and they have the option to cancel or modify their subscriptions at any time. The integrated technology aids in facilitating efficient customer transactions, telehealth consultations, and order fulfillment, ultimately providing cost advantages and generating robust gross margins.

Hims & Hers employs diverse marketing strategies, leveraging social media, traditional media, and in-store promotions to drive brand awareness and customer acquisition. Continued investment in expanding product lines and services, coupled with scaling the platform effectively, forms a core part of the company’s growth strategy.

C. Growth Opportunities

Several avenues provide Hims & Hers with significant growth potential:

  • Customer Acquisition: The company aims to enhance its brand recognition by offering innovative, consumer-led health solutions. Its marketing approach emphasizes education and destigmatization of healthcare inquiries, particularly among first-time customers.
  • Exploration of New Markets: Hims & Hers continues to explore international expansion with successful operations established in the United Kingdom, while evaluating future entrants into European markets and beyond.
  • Expansion of Product Offerings: There is an ongoing commitment to increasing the range of healthcare conditions addressed by its platform, pursuing opportunities for therapies that are well-suited for telehealth delivery.
  • Strengthened Supply Chain and Logistics: With dedicated mail-order pharmacies, including XeCare and Apostrophe Pharmacy, the company aims to lower costs and improve efficiencies in drug fulfillment and customer order management.

D. Affiliated Medical Groups and Provider Network

To navigate the complexities of healthcare regulation, Hims & Hers has established relationships with Affiliated Medical Groups—professional entities composed solely of licensed medical professionals. These affiliations permit the provision of clinical services on the Hims & Hers platform under comprehensive agreements that delineate provider responsibilities.

The affiliated groups employ a range of healthcare providers who deliver telehealth consultations and services. Administrative services provided by Hims & Hers include IT support, patient billing, and provider credentialing. These partnerships are critical to ensuring compliance with healthcare regulations while maintaining the quality and efficiency of patient care.

E. Regulatory Environment

Hims & Hers operates within a heavily regulated environment, adhering to complex healthcare laws at state and federal levels, particularly with regards to telehealth practices and patient privacy. The company differentiates itself by accepting payments solely from customers, thereby circumventing certain regulatory frameworks imposed on traditional payor relationships.

In the realm of telehealth, the regulation of the practice varies significantly by state, which necessitates ongoing diligence to ensure compliance with licensure laws applicable to healthcare providers. Additionally, adherence to FDA guidelines for product safety governs the offerings provided through its platform.

F. Intellectual Property

Intellectual property management plays a central role in protecting Hims & Hers' technological innovations and brand integrity. The company has established a suite of trademarks for its products and services and maintains confidentiality procedures. Despite these protective measures, the ability to uphold intellectual property rights in a competitive marketplace remains a top priority.

As of the latest reports, Hims & Hers holds numerous trademark registrations both in the U.S. and internationally, alongside pending applications. While currently lacking registered patents, the strategic management of its proprietary technology and brand assets positions the company for continued growth.

Stock Infos

SectorInformation Technology
IndustryComputer Software and Services
CEOMr. Dudum

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.